Finasteride


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Benign prostatic hyperplasia 5 mg once daily. Male pattern baldness 1 mg once daily
Dosage Details
Oral
Benign prostatic hyperplasia
Adult: 5 mg once daily for at least 6 mth.

Oral
Male pattern baldness
Adult: 1 mg once daily for at least 3 mth.
Administration
May be taken with or without food.
Contraindications
Women, childn and adolescents. Pregnancy and lactation.
Special Precautions
Men at risk of obstructive uropathy. Hepatic impairment.
Adverse Reactions
Sexual dysfunction (e.g. decreased libido, erectile dysfunction, ejaculation disorders including reduced vol of ejaculate), gynaecomastia, testicular pain, hypersensitivity reactions (e.g. swelling of lips and face, pruritus, urticaria, rashes, angioedema); decreased prostate-specific antigen (PSA) levels; depression, male breast cancer, orgasm disorders.
Patient Counseling Information
Women who are or may become pregnant should avoid contact w/ crushed or broken tablets.
MonitoringParameters
Monitor prostate-specific antigen (PSA) levels.
Lab Interference
May mask serum markers (PSA) for prostate cancer.
Action
Description: Finasteride is a synthetic 4-azasteroid compound and a competitive inhibitor of both tissue and hepatic 5α-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone (DHT) levels. In male pattern baldness, finasteride decreases scalp DHT levels to levels found in hairy scalp. Reduced serum DHT, increases hair regrowth and slows hair loss.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Bioavailability: Approx 80%. Time to peak plasma concentration: 1-2 hr.
Distribution: Crosses the blood-brain barrier and distributed into seminal fluid. Volume of distribution: 76 L. Plasma protein binding: Approx 90%.
Metabolism: Undergoes hepatic metabolism primarily by CYP3A4 isoenzyme.
Excretion: Via urine (39%) and faeces (57%) as metabolites. Terminal half-life: Approx 6 hr.
Chemical Structure

Chemical Structure Image
Finasteride

Source: National Center for Biotechnology Information. PubChem Database. Finasteride, CID=57363, https://pubchem.ncbi.nlm.nih.gov/compound/Finasteride (accessed on Jan. 21, 2020)

Storage
Store at 20-25°C. Protect from light.
References
Anon. Finasteride. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 12/11/2014.

Anon. Finasteride. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/11/2014.

Buckingham R (ed). Finasteride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/11/2014.

Finasteride Tablet, Film-coated (Accord Healthcare, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/11/2014.

Disclaimer: This information is independently developed by MIMS based on Finasteride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Finast
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in